BioSpace News Archive

Alkermes is exploring the potential spin-out of its cancer business into an independent, publicly traded company. Alkermes offered further details during an investor call Wednesday.

Viracta Therapeutics, Inc. announced that company leadership is scheduled to present and participate in one-on-one meetings at four investor conferences in November.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

Amgen will host a webcast call for the investment community in conjunction with the American Heart Association Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA®.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the close of U.S. markets.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2022.

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced the Company’s third quarter 2022 financial results will be released after market close on Wednesday, November 9th.

Tyra Biosciences, Inc. announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.

10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2022.